EMEA-002899-PIP01-20-M01

Table of contents

Key facts

Invented name
Xevudy
Active substance
Sotrovimab
Therapeutic area
Infectious diseases
Decision number
P/0468/2021
PIP number
EMEA-002899-PIP01-20-M01
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection/infusion
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
  • Intravenous use
  • Intramuscular use
Contact for public enquiries
GlaxoSmithKline Trading Services Ltd

Tel. +1 4388998201
E-mail: eu.paediatric-plans@gsk.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating